|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Predictive value of quantitative diffusion-weighted imaging and 18-F-FDG-PET in head and neck squamous cell carcinoma treated by (chemo)radiotherapy.
|
30927958 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Palatine tonsil SUVmax on FDG PET-CT as a discriminator between benign and malignant tonsils in patients with and without head and neck squamous cell carcinoma of unknown primary.
|
30454841 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association of metabolic and genetic heterogeneity in head and neck squamous cell carcinoma with prognostic implications: integration of FDG PET and genomic analysis.
|
31754877 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the performance of <sup>18</sup> F-fluorodeoxy-d-glucose positron emission tomography-computed tomography (<sup>18</sup> F-FDG PET/CT) in identifying local failure and regional failure following curative radiotherapy or surgery for head and neck squamous cell carcinoma.
|
30456825 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Imaging with FDG PET/CT can be recommended in patients with recurrent HNSCC prior to putative salvage surgery.
|
31297609 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to examine whether staging with <sup>18</sup>F-FDG PET/CT better predicts survival in patients with recurrent head and neck squamous cell carcinoma (HNSCC) than chest x-ray (CXR) plus head and neck MRI or chest CT (CCT) plus head and neck MRI.
|
30315144 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consecutive patients with HNSCC referred in our department for a pre-therapeutic FDG PET/CT from January to March 2016 were retrospectively included.
|
30921388 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The objective of this study is to evaluate the diagnostic and prognostic ability of fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) scan in patients with squamous cell carcinoma of the head and neck treated with chemoradiotherapy or radiotherapy only.
|
31169226 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Positron emission tomography (PET) with 2-deoxy-2-[<sup>18</sup>F]fluoro-D-glucose ([<sup>18</sup>F]FDG) is increasingly used for diagnosing and staging, as well as for monitoring of treatment of HNSCC.
|
29931433 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
<b>Conclusions and significance:</b><sup>18</sup>F-FDG PET/CT or conventional imaging is comparable with regard to detecting distant metastases of recurrent HNSCC.
|
31274365 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
FDG PET/CT has a high negative predictive value in patients with head and neck squamous cell carcinoma who responds completely to non-operative therapy.
|
30166429 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In 12 patients who underwent surgical treatment of primary SCCHN (Stage III-IV) F18-FDG PET/CT image-fusion was performed on a 3D navigation-system based workstation.
|
29526413 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical value of <sup>18</sup> FDG PET/CT in screening for distant metastases in head and neck squamous cell carcinoma.
|
29377508 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
• FDG-PET/DWIMRI yields excellent results for the detection of post-radio(chemo)therapy HNSCC recurrence.
|
28812148 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prediction of ultrasound guided fine needle aspiration cytology results by FDG PET-CT for lymph node metastases in head and neck squamous cell carcinoma patients.
|
30489180 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to assess the value of pretreatment <sup>18</sup>F-FDG PET texture analysis for the prediction of treatment failure in primary head and neck squamous cell carcinoma (HNSCC) treated with concurrent chemoradiation therapy.
|
30363632 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Methods:</b> Functional MRI and <sup>18</sup>F-FDG PET were used to visualize and quantify imaging biomarkers associated with drug response within size-matched EGFR TKI-resistant CAL 27 (CAL<sup>R</sup>) and sensitive (CAL<sup>S</sup>) HNSCC xenografts <i>in vivo</i>, and pathological correlates sought.
|
30083516 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
To study an original 3D visualization of head and neck squamous cell carcinoma extending to the mandible by using [18F]-NaF PET/CT and [18F]-FDG PET/CT imaging along with a new innovative FDG and NaF image analysis using dedicated software.
|
29567343 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Relationships between histogram analysis of ADC values and complex 18F-FDG-PET parameters in head and neck squamous cell carcinoma.
|
30188926 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our purpose was to examine whether staging of head and neck squamous cell carcinoma (HNSCC) by upfront <sup>18</sup>F-FDG PET/CT (i.e., on the day of biopsy and before the biopsy) discriminates survival better than the traditional imaging strategies based on chest x-ray plus head and neck MRI (CXR/MRI) or chest CT plus head and neck MRI (CCT/MRI).
|
28864630 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET.
|
30157883 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Early intra-treatment changes in FDG-PET, DW and DCE MRI-derived parameters are predictive of ultimate response to chemoradiation in HNSCC.
|
29164301 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Posttreatment <sup>18</sup>F-FDG PET/CT surveillance helps to properly detect recurrence and to predict the survival following treatment of HNSCC.
|
28027517 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Spinal Metastasis Characterized on FDG PET/CT in Head and Neck Squamous Cell Carcinoma.
|
28922190 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate the prognostic impact of maximum standardized uptake value (SUV<sub>max</sub>) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) undergoing pretreatment [F-18] fluoro-D-glucose-positron emission tomography/computed tomography (FDG PET/CT) imaging.
|
28540535 |
2017 |